Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial

Hiddo J.L. Heerspink(University Medical Center Groningen), Rey Isidto, Frederik Persson, Naoki Kashihara(Kawasaki Medical School), Tom Greene(University Medical Center Groningen), Walter Douthat, Stuart Pocock(London School of Hygiene & Tropical Medicine), Magnus Lindberg(University of Gävle), Fan Fan Hou(Southern Medical University), John J.V. McMurray(University of Glasgow), István Wittmann(FIND), David Z.I. Cherney(University Health Network), Marc A. Pfeffer(Brigham and Women's Hospital), Andrew S. Levey(Tufts Medical Center), Glenn M. Chertow(Stanford Health Care), Dinesh Khullar(Max Super Speciality Hospital), Roberto Pecoits‐Filho(Pontifícia Universidade Católica do Paraná), Johannes F.E. Mann(Katholische Stiftungshochschule München), Pernilla Holmgren, Ricardo Correa‐Rotter(University Medical Center Groningen), Pécsi Tudományegyetem, David C. Wheeler(University College London), Theresa Hallberg, Bergur V. Stefánsson(University Medical Center Groningen), Peter Rossing(Steno Diabetes Centers), Karl Swedberg(Brigham and Women's Hospital), Claes Held(Uppsala University), Heidi Christ‐Schmidt(Statistics Collaborative), Nish Chaturvedi(Imperial College London), Peter Ivanovich, Roberto D. Toto(University Medical Center Groningen), Christoph Varenhorst, Richardo Correa-Rotter(Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán), R Correa-Rotter(University of Utah), FF Hou(Nanfang Hospital), Elizabeth Escudero, Hermann Haller(Medizinische Hochschule Hannover), Jean L. Rouleau(Montreal Heart Institute), Anna Maria Langkilde(AstraZeneca (Sweden))
Nephrology Dialysis Transplantation
December 10, 2019
Cited by 216


Related Papers